title: A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG).
authors.affiliation: Manitoba Cancer Treatment and Research Foundation, Winnipeg, Canada.
authors.forename: T
authors.initials: T
authors.lastname: Shore
authors.forename: E
authors.initials: E
authors.lastname: Eisenhauer
authors.forename: I
authors.initials: I
authors.lastname: Quirt
authors.forename: K
authors.initials: K
authors.lastname: Belanger
authors.forename: R
authors.initials: R
authors.lastname: Lohmann
authors.forename: H
authors.initials: H
authors.lastname: Silver
authors.forename: G
authors.initials: G
authors.lastname: Wielgosz
mesh_terms: D000880:Anthraquinones / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002170:Canada; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D011720:Pyrazoles / Q000627:therapeutic use*
chemical_list: D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; C046658:teloxantrone